MINNEAPOLIS--(BUSINESS WIRE)--Clinical trial data presented at the 15th Annual Meeting of the North American Neuromodulation Society demonstrate the AdaptiveStim™ with RestoreSensor™ neurostimulation system from Medtronic (NYSE: MDT) provides clinical benefits for many patients, including effective pain relief and convenience, compared to systems without position-adaptive stimulation technology.
